What is the latest APLLTD stock price?
The latest stored price for APLLTD is Rs 821.75 as of 2026-08-21.
gimli
APLLTD stock AI analysis
APLLTD Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
ALEMBIC PHARMA LTD is a small-cap stock in Healthcare. This Gimli page shows the latest available APLLTD price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹821.75
1W return
-1.14%
1M return
-1.42%
3M return
+9.73%
6M return
+7.69%
1Y return
-15.10%
Market cap
₹16,152.57 cr
PE
23.33
PB
2.85
ROE
+12.75%
ROCE
+8.50%
RSI
51.38
Turnover
₹2.92 cr
Why it can matter in screens
- Momentum: APLLTD is above 50DMA, above 200DMA; RSI is 51.38.
- Returns: 1D +0.94%, 1W -1.14%, 1M -1.42%, 3M +9.73%, 1Y -15.10%.
- Trend levels: 52W high ₹855.90, 52W low ₹706.90, off high -3.99%.
- Liquidity: latest turnover is ₹2.92 cr; volume vs 20D is +0.30%.
- Valuation/profitability: PE 23.33, PB 2.85, ROE +12.75%, ROCE +8.50%.
- Growth: 3Y sales CAGR +10.12%, 3Y profit CAGR +25.42%.
Quick Answers
Is APLLTD above its 50DMA and 200DMA?
APLLTD is above 50DMA, above 200DMA. The latest 50DMA is 809.51 and the latest 200DMA is 794.92.
What are APLLTD PE, ROE and ROCE?
APLLTD has PE 23.33, ROE +12.75%, and ROCE +8.50% in Gimli's latest available snapshot.
How has APLLTD performed recently?
APLLTD has returned -1.42% over 1 month, +9.73% over 3 months, and -15.10% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 2,149.77 cr | 347.18 cr | 173.07 cr | 8.80 |
| 2026-03-31 | 1,847.72 cr | 229.77 cr | 202.70 cr | 10.31 |
| 2025-12-31 | 1,876.31 cr | 264.93 cr | 132.97 cr | 6.76 |
| 2025-09-30 | 1,917.00 cr | 322.60 cr | 183.71 cr | 9.40 |
| 2025-06-30 | 1,710.72 cr | 287.39 cr | 154.38 cr | 7.85 |
| 2025-03-31 | 1,769.64 cr | 285.46 cr | 156.89 cr | 7.98 |
| 2024-12-31 | 1,692.74 cr | 270.08 cr | 138.42 cr | 7.01 |
| 2024-09-30 | 1,647.98 cr | 269.74 cr | 153.41 cr | 7.79 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 7,344.90 cr | 1,106.13 cr | 674.77 cr | 34.33 |
| 2025-03-31 | 6,672.08 cr | 1,064.53 cr | 583.42 cr | 29.68 |
| 2024-03-31 | 6,112.11 cr | 960.69 cr | 615.82 cr | 31.33 |
| 2023-03-31 | 5,499.77 cr | 680.19 cr | 341.99 cr | 17.40 |
| 2022-03-31 | 5,086.55 cr | 929.90 cr | 543.55 cr | 27.65 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 8,762.59 cr | 196.37 cr | 1,429.94 cr | 5,668.98 cr |
| 2025-03-31 | 7,772.94 cr | 83.48 cr | 1,257.50 cr | 5,189.52 cr |
| 2024-03-31 | 6,445.58 cr | 120.21 cr | 513.16 cr | 4,818.20 cr |
| 2023-03-31 | 6,182.83 cr | 75.48 cr | 722.01 cr | 4,370.46 cr |
| 2022-03-31 | 7,122.03 cr | 61.09 cr | 717.11 cr | 5,237.55 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 782.73 cr | 287.85 cr | n/a |
| 2025-03-31 | 87.97 cr | -475.65 cr | n/a |
| 2024-03-31 | 803.20 cr | 475.73 cr | n/a |
| 2023-03-31 | 723.95 cr | 280.54 cr | n/a |
| 2022-03-31 | 552.35 cr | 126.71 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +69.87% | +4.18% | +15.94% | +8.73% | +10.01% | +0.00% |
| 2026-03-31 | +69.74% | +4.25% | +16.18% | +8.18% | +9.83% | +0.00% |
| 2025-12-31 | +69.74% | +4.24% | +16.17% | +8.22% | +9.85% | +0.00% |
| 2025-09-30 | +69.74% | +4.05% | +16.30% | +8.55% | +9.92% | +0.00% |
| 2025-06-30 | +69.67% | +3.96% | +16.46% | +9.05% | +9.90% | +0.00% |
| 2025-03-31 | +69.67% | +3.94% | +16.43% | +9.20% | +9.96% | +0.00% |
| 2024-12-31 | +69.61% | +4.17% | +16.06% | +8.96% | +10.16% | +0.00% |
| 2024-09-30 | +69.61% | +3.94% | +16.05% | +8.90% | +10.39% | +0.00% |
| 2024-06-30 | +69.61% | +4.32% | +15.47% | +8.05% | +10.60% | +0.00% |
| 2024-03-31 | +69.61% | +4.46% | +15.38% | +7.82% | +10.54% | +0.00% |
| 2023-12-31 | +69.61% | +4.52% | +14.50% | +7.71% | +11.37% | +0.00% |
| 2023-09-30 | +69.61% | +4.51% | +14.22% | +7.33% | +11.67% | n/a |
| 2023-06-30 | +69.61% | +4.35% | +13.64% | +6.64% | +12.40% | +0.00% |
| 2023-03-31 | +69.61% | +4.55% | +13.31% | +6.47% | +12.53% | +0.00% |
| 2022-12-31 | +69.61% | +4.99% | +12.76% | +5.87% | +12.65% | +0.00% |
| 2022-09-30 | +69.61% | +5.32% | +12.54% | +5.36% | +12.53% | +0.00% |
| 2022-06-30 | +69.61% | +0.00% | +18.09% | n/a | n/a | +0.00% |
| 2022-03-31 | +69.61% | +0.00% | +17.76% | n/a | n/a | n/a |
| 2021-12-31 | +69.48% | +0.00% | +17.50% | n/a | n/a | +0.00% |
| 2021-09-30 | +69.48% | +0.00% | +16.94% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 456,449.49 cr | 37.677543 | +15.50% | +15.99% |
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 165,719.79 cr | 75.983398 | +17.33% | +34.25% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| CIPLA | CIPLA LTD | 115,693.19 cr | 34.304976 | +10.25% | -10.08% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| LUPIN | LUPIN LIMITED | 100,669.80 cr | 14.727517 | +34.34% | +12.19% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
Try these prompts
- Analyze ALEMBIC PHARMA with valuation, momentum and industry peers
- Compare APLLTD with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare APLLTD with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.